A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

Conditions

• Multiple Myeloma

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Talquetamab — DRUG
  Talquetamab will be administered as a SC injection.
• Pomalidomide — DRUG
  Pomalidomide will be administered orally.
• Teclistamab — DRUG
  Teclistamab will be administered as a SC injection.
• Elotuzumab — DRUG
  Elotuzumab will be administered intravenously.
• Dexamethasone — DRUG
  Dexamethasone will be administered either orally or intravenously.
• Bortezomib — DRUG
  Bortezomib will be administered as a SC injection.

Study Details

The purpose of this study is to compare the effectiveness of either talquetamab plus pomalidomide (Tal-P) or talquetamab plus teclistamab (Tal-Tec) with elotuzumab, pomalidomide, and dexamethasone (EPd) or pomalidomide, bortezomib, and dexamethasone (PVd).

Key Dates

Start date

Jan 22, 2024

Status verified

Jun 2026

Primary completion

Apr 1, 2026

Completion

Dec 31, 2028

Study Design

Enrollment

795 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Arm A: Talquetamab + Pomalidomide (Tal-P)
  Participants will receive talquetamab as subcutaneous (SC) injections; pomalidomide will be self-administered as a single dose orally; dexamethasone may be given orally or intravenously as a pretreatment medication and study drug.
• Experimental: Arm B: Talquetamab + Teclistamab (Tal-Tec)
  Participants will receive teclistamab in combination with talquetamab both as SC injection; dexamethasone may be given orally or intravenously as a pretreatment medication and study drug.
• Active Comparator: Arm C: Elotuzumab+ Pomalidomide+Dexamethasone (EPd) or Pomalidomide+Bortezomib+Dexamethasone (PVd)
  Participants will either receive elotuzumab intravenous (IV) injection in combination with pomalidomide and dexamethasone orally; or pomalidamide orally in combination with bortezomib SC injection and dexamethasone orally as per investigator choice. Dexamethasone will be administered as a pretreatment medication.

Primary Outcome Measure

Progression Free Survival (PFS) [ Time Frame: Up to 3 years 5 months ]

Central Contacts

• Study Contact
  844-434-4210
  [email protected]

Locations (49)

Related coverage on Hipa.ai

• Talquetamab Phase 3 Trial for Multiple Myeloma Reaches Primary Completion
  Talquetamab · Apr 23, 2026 · ClinicalTrials.gov
• Talquetamab Phase 3 Trial for Relapsed/Refractory Myeloma Reaches Primary…
  Talquetamab · Apr 1, 2026 · ClinicalTrials.gov

Find similar trials in Clovis, CA

Related Studies

• Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
  Recruiting · Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey
• Family Study of Lymphoproliferative Disorders
  Recruiting · Mayo Clinic · Rochester, Minnesota
• Collection of Tissue Samples for Cancer Research
  Recruiting · National Cancer Institute (NCI) · Sacramento, California
• Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
  Recruiting · Ohio State University Comprehensive Cancer Center · Columbus, Ohio